BioSpace News Archive

Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) (“Adamis”) announced today a license to commercialize Tempol, a novel patented investigational drug for the treatment of Coronavirus (COVID-19). The license includes the worldwide use of Tempol for the treatment of all respiratory diseases including asthma, respiratory syncytial virus, influenza and COVID-19. In addition, the exclusive license includes the use of Tempol for reducing radiation

Redox, Inc., the leading interoperability platform for healthcare data exchange, is working with FDA-authorized COVID-19 testing company Curative to safely connect patient data to state public health departments for notification of results

Lawley Pharmaceuticals and Tanner Pharma Group announced today that they have initiated a global named patient program for AndroFeme ® 1 testosterone cream for women. AndroFeme ® 1 is licensed by Western Australian regulatory authorities and is indicated for the treatment of postmenopausal women with hypoactive sexual desire dysfunction (HSDD). Lawley has appointed Tanner Pharma Group as

Rafarma Pharmaceuticals, Inc. is happy to announce commencement of tests for its new product “HempySleep”.

NIDDK study continues to look at possible factors that lead to the development of the diseases in children

Today, Sparta Systems, Inc., the leading provider of quality management solutions for life sciences, announced that American Regent, Inc., a top-10 injectable manufacturer, has chosen TrackWise Digital® as its next generation cloud platform for manufacturing, clinical, and supplier management.

Jennifer M. Carter, Vice President, Venture Operations at McKesson Ventures, joins the board of directors of the nation’s leading provider of remote medical documentation and live clinical support services. [15-June-2020] SAN FRANCISCO , June 15, 2020 /PRNewswire/ -- Augmedix today announced that Jennifer M. Carter , Vice President, Venture Operations at McKes

Abiomed, maker of the Impella heart pump, announced it has appointed Charles Simonton, M.D., as vice president and chief medical officer.

Humanigen, Inc., a clinical stage biopharmaceutical company focused on preventing and treating cytokine storm with lenzilumab, the company’s proprietary Humaneered® anti-human granulocyte macrophage-colony stimulating factor monoclonal antibody, announced data on the first clinical use of lenzilumab in 12 COVID-19 patients.

Appili Therapeutics Inc. is pleased to announce that its common shares began trading on the OTCQX Best Market®.